Increase(300713)

Search documents
英可瑞:公司目前经营正常
Zheng Quan Ri Bao· 2025-10-10 11:10
(文章来源:证券日报) 证券日报网讯英可瑞10月10日在互动平台回答投资者提问时表示,公司目前经营正常,没有应披露未披 露的信息。 ...
英可瑞:截至2025年9月19日公司股东总户数约1.47万户
Zheng Quan Ri Bao Wang· 2025-09-23 09:44
证券日报网讯英可瑞(300713)9月23日在互动平台回答投资者提问时表示,截至2025年9月19日,公司 股东总户数约1.47万户。 ...
英可瑞:截至9月10日股东总户数约1.49万户
Zheng Quan Ri Bao Wang· 2025-09-15 09:17
证券日报网讯 英可瑞(300713)9月15日在互动平台回答投资者提问时表示,截至2025年9月10日,公 司股东总户数约1.49万户。 ...
英可瑞(300713) - 上海市锦天城(深圳)律师事务所关于深圳市英可瑞科技股份有限公司2025年第一次临时股东大会的法律意见书
2025-09-12 10:08
上海市锦天城(深圳)律师事务所 关于深圳市英可瑞科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 上海市锦天城(深圳)律师事务所 法律意见书 上海市锦天城(深圳)律师事务所 关于深圳市英可瑞科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 致:深圳市英可瑞科技股份有限公司 上海市锦天城(深圳)律师事务所(以下简称"本所")接受深圳市英可瑞科 技股份有限公司(以下简称"公司")委托,就公司召开 2025 年第一次临时股东 大会(以下简称"本次股东大会")的有关事宜,根据《中华人民共和国公司法》 (以下简称《公司法》)《上市公司股东会规则》等法律、法规、规章和其他规范 性文件以及《深圳市英可瑞科技股份有限公司章程》(以下简称《公司章程》)的 有关规定,出具本法律意见书。 为出具本法律意见书,本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责,遵循了勤勉尽责和诚实信用原则,对本次股东大会所涉及的相关事 项进行了必要的核查和验证,核查了本所认为出具该法律意见书所需的相关文件、 资料,并参加了公司本次股东大会的全 ...
英可瑞(300713) - 2025年第一次临时股东大会决议公告
2025-09-12 10:07
证券代码:300713 证券简称:英可瑞 公告编号:2025-039 深圳市英可瑞科技股份有限公司 2025年第一次临时股东大会决议公告 (2)网络投票:通过深圳证券交易所交易系统进行网络投票的具体时间为 2025年9月12日上午9:15—9:25,9:30—11:30,下午13:00—15:00;通过深圳证 券交易所互联网投票的具体时间为:2025年9月12日上午9:15至下午15:00期间的 任意时间。 3.会议地点:深圳市南山区中山园路1001号国际E城E1栋11楼公司大会议室。 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 1.本次股东大会无增加、变更、否决议案的情形。 2.本次股东大会未涉及变更前次股东大会决议情况。 一、会议召开和出席情况 1.股东大会届次:2025年第一次临时股东大会 2.会议召开的日期、时间: (1)现场会议召开:2025年9月12日下午14:30时开始 4.会议召开方式:本次股东大会采用现场表决与网络投票相结合的方式。 5.股东大会的召集人:本次股东大会的召集人为董事会。 6.会议主持人:公司董事长尹伟先生。 7 ...
调研速递|英可瑞接受天治基金等2家机构调研 透露多项业务关键数据与规划要点
Xin Lang Cai Jing· 2025-09-09 12:33
Group 1 - The core viewpoint of the news is that Shenzhen Inke Rui Technology Co., Ltd. is actively engaging with investors and showcasing its business performance and future plans, particularly in the electric vehicle charging and power supply sectors [1][2]. - In the first half of 2025, the revenue from electric vehicle charging power products reached 103 million yuan, representing a year-on-year growth of 91.05%. The revenue from power operation products was 20.11 million yuan, with a slight increase of 0.30%, while other power products generated 74.21 million yuan, marking a growth of 77.36% [1]. - The company emphasizes technological innovation to enhance product competitiveness and market expansion, although it has not confirmed profitability for the current year [1][2]. Group 2 - The overseas business layout shows that in the first half of 2025, the company's subsidiary achieved a revenue of 23.21 million yuan and a net profit of 5.45 million yuan, indicating a focus on international markets and tailored product development [2]. - The HVDC power supply and system are primarily used in data center rooms, with the HVDC power module utilizing air cooling technology [2]. - The company is committed to long-term incentive mechanisms and will consider various factors for any future plans, ensuring compliance with regulatory procedures and timely disclosures [2].
英可瑞:接受天治基金调研
Mei Ri Jing Ji Xin Wen· 2025-09-09 11:32
2024年1至12月份,英可瑞的营业收入构成为:新能源汽车行业占比56.35%,其他电源行业占比 26.17%,电力行业占比17.48%。 截至发稿,英可瑞市值为29亿元。 每经头条(nbdtoutiao)——雷军挥泪"斩"王腾,小米爱将泄密"失街亭",大厂正风肃纪"拼牙口" 每经AI快讯,英可瑞(SZ 300713,收盘价:18.13元)发布公告称,2025年9月9日15:00-16:00,英可瑞 接受天治基金调研,公司董事兼总经理王孟腾、财务总监孙晶,董事会秘书邓琥、证券事务代表向慧参 与接待,并回答了投资者提出的问题。 (记者 曾健辉) ...
英可瑞(300713) - 300713英可瑞:2025年09月09日投资者关系活动记录表
2025-09-09 11:13
Group 1: Business Performance - In the first half of 2025, the company's revenue from electric vehicle charging power products reached ¥103,039,732.65, a year-on-year increase of 91.05% [2] - Revenue from electric power operation products was ¥20,105,518.20, with a slight year-on-year growth of 0.30% [2] - Other power products generated revenue of ¥74,212,606.30, reflecting a year-on-year increase of 77.36% [2] Group 2: Market Strategy - The company aims to enhance product competitiveness and market expansion by driving technological innovation [2] - Plans to optimize and integrate resources to support core business development and improve operational management strategies [3] Group 3: International Business Development - The company's subsidiary, Shenzhen Yingkerui International Holdings Co., Ltd., achieved revenue of ¥23,205,729.95 and a net profit of ¥5,452,348.36 in the first half of 2025 [4] - The company is focused on overseas market development, targeting product research and development to meet diverse customer needs [4] Group 4: Product Development - The HVDC power supply and systems are primarily used in data center facilities, with current products utilizing air cooling technology [5] Group 5: Employee Incentives - The company emphasizes the establishment of long-term incentive mechanisms, including potential stock options, to foster mutual growth with employees [6] Group 6: Information Disclosure - The company ensured that the investor relations activity did not involve any undisclosed significant information [7]
英可瑞:截至2025年8月29日公司股东总户数约1.45万户
Zheng Quan Ri Bao Wang· 2025-09-02 11:13
Group 1 - The company, InnoCare Pharma (英可瑞), reported that as of August 29, 2025, the total number of shareholders is approximately 14,500 [1]
英可瑞(300713)2025年中报简析:营收上升亏损收窄,存货明显上升
Zheng Quan Zhi Xing· 2025-08-27 11:50
Core Viewpoint - The financial report of Yingkerui (300713) for the first half of 2025 shows significant revenue growth but continued net losses, indicating potential challenges in profitability despite increased sales [1]. Financial Performance Summary - Total revenue for the first half of 2025 reached 197 million yuan, a year-on-year increase of 66.77% compared to 118 million yuan in the same period of 2024 [1]. - The net profit attributable to shareholders was -25.81 million yuan, improving by 11.20% from -29.06 million yuan in the previous year [1]. - The gross margin increased to 21.52%, up by 4.96% from 20.50% in 2024, while the net margin improved to -14.30%, a 49.69% increase from -28.42% [1]. - The total of selling, administrative, and financial expenses was 39.49 million yuan, accounting for 20.01% of revenue, a decrease of 21.07% year-on-year [1]. - The company's cash flow from operating activities showed a significant decline of 259.53%, attributed to increased payments to employees [3][5]. Balance Sheet Changes - Inventory increased by 58.68%, indicating a buildup of stock likely due to new product development and existing orders [1][4]. - Accounts receivable rose by 10.85% to 201 million yuan, reflecting increased sales [1][4]. - Interest-bearing liabilities increased by 35.81% to 140 million yuan, indicating higher debt levels [1]. - Cash and cash equivalents decreased by 43.50% to 45.86 million yuan, highlighting liquidity concerns [1]. Cash Flow Analysis - The net cash flow from financing activities decreased by 81.95%, primarily due to reduced bank borrowings [5]. - The net increase in cash and cash equivalents dropped by 247.35%, driven by higher employee payments and decreased borrowings [5]. Operational Insights - The increase in sales expenses by 25.78% and administrative expenses by 37.44% suggests rising operational costs, potentially impacting future profitability [4]. - The company has experienced a historical average return on invested capital (ROIC) of 1.48%, with a notably poor ROIC of -13.36% in 2024, indicating challenges in generating returns on investments [5].